72 related articles for article (PubMed ID: 31103601)
1. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
2. Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
Devlies W; Eckstein M; Cimadamore A; Devos G; Moris L; Van den Broeck T; Montironi R; Joniau S; Claessens F; Gevaert T
Cells; 2020 Nov; 9(11):. PubMed ID: 33212909
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
Leibrand CR; Price DK; Figg WD
Cancer Biol Ther; 2016 May; 17(5):467-9. PubMed ID: 26985596
[TBL] [Abstract][Full Text] [Related]
4. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Lundberg A; Zhang M; Aggarwal R; Li H; Zhang L; Foye A; Sjöström M; Chou J; Chang K; Moreno-Rodriguez T; Shrestha R; Baskin A; Zhu X; Weinstein AS; Younger N; Alumkal JJ; Beer TM; Chi KN; Evans CP; Gleave M; Lara PN; Reiter RE; Rettig MB; Witte ON; Wyatt AW; Feng FY; Small EJ; Quigley DA
Cancer Res; 2023 Aug; 83(16):2763-2774. PubMed ID: 37289025
[TBL] [Abstract][Full Text] [Related]
5. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.
Chakrani Z; Mellgard G; Saffran N; McCroskery S; Taylor N; Patel M; Liaw B; Galsky M; Oh WK; Tsao CK; Patel VG
Am J Clin Oncol; 2024 Jun; 47(6):271-278. PubMed ID: 38344754
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor Alterations.
Stitz R; Stoiber F; Silye R; Vlachos G; Andaloro S; Rebhan E; Dunzinger M; Pühringer F; Gallo C; El-Heliebi A; Heitzer E; Hauser-Kronberger C
J Mol Diagn; 2024 Jun; 26(6):467-478. PubMed ID: 38522838
[TBL] [Abstract][Full Text] [Related]
10. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
Conteduca V; Mosca A; Brighi N; de Giorgi U; Rescigno P
Cells; 2021 Jan; 10(1):. PubMed ID: 33478015
[TBL] [Abstract][Full Text] [Related]
11. Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer.
Du M; Huang CC; Tan W; Kohli M; Wang L
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32752286
[TBL] [Abstract][Full Text] [Related]
12. Building a hit list for the fight against metastatic castration resistant prostate cancer.
Strope JD; Price DK; Figg WD
Cancer Biol Ther; 2016; 17(3):231-2. PubMed ID: 26822877
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Nixon AB; Liu Y; Yang Q; Luo B; Starr MD; Brady JC; Kelly WK; Beltran H; Morris MJ; George DJ; Armstrong AJ; Halabi S
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347114
[TBL] [Abstract][Full Text] [Related]
14. Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.
Su MC; Lee AM; Zhang W; Maeser D; Gruener RF; Deng Y; Huang RS
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794139
[TBL] [Abstract][Full Text] [Related]
15. Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
Büttner T; Klümper N; Weiten R; Lossin P; Latz S; Jacobs C; Ritter M; Hauser S; Ellinger J; Krausewitz P
Prostate; 2024 May; ():. PubMed ID: 38751206
[TBL] [Abstract][Full Text] [Related]
16. Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer.
Sassi A; You L
Cells; 2024 Mar; 13(7):. PubMed ID: 38607014
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signature of castrate resistant prostate cancer.
Dixcy Jaba Sheeba JM; Hegde S; Tamboli N; Nadig N; Keshavamurthy R; Ranganathan P
Gene; 2024 May; 925():148603. PubMed ID: 38788815
[TBL] [Abstract][Full Text] [Related]
18. Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer.
Kattan MW; Bukowski RM
Front Oncol; 2020; 10():602992. PubMed ID: 33330103
[No Abstract] [Full Text] [Related]
19. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE; Day A; Bergom HE; Larson G; Ali A; Ludwig M; Boytim E; Coleman I; Corey E; Plymate SR; Nelson PS; Hwang JH; Drake JM
bioRxiv; 2023 Aug; ():. PubMed ID: 37577653
[TBL] [Abstract][Full Text] [Related]
20. Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer.
Huang J; Du M; Soupir A; Wang L; Tan W; Kalari KR; Kilari D; Park J; Huang CC; Kohli M; Wang L
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
